Vivione Biosciences

Press Releases

Vivione Biosciences Finalizes Agreement with University of Rochester for Exclusive Worldwide Rights to Novel Infectious Disease-Related Biomarker

DALLAS, Texas – Vivione Biosciences Inc. ("Vivione") (TSXV: VBI), announced today the execution of an Option Agreement with the University of Rochester to gain exclusive worldwide rights to a novel biomarker for infectious disease-related diagnostics. This acquisition is one of many steps Vivione is taking to strategically position the company's entry into the clinical diagnostics market. Through the Option Agreement, Vivione will also have the ability to obtain exclusive worldwide rights to a therapeutic peptide targeting the same molecule identified by the biomarker. During the option period, Vivione will work with researchers at the University of Rochester in the Departments of Immunology and Pulmonology in order to expand upon existing data in clinical patient populations.

Vivione Biosciences Inc. Announces a Research Collaboration With Northwestern University Feinberg School of Medicine

DALLAS, TX-- (Marketwired - May 11, 2015 ) -Vivione Biosciences Inc. ("Vivione" or the "Company" ) (TSX VENTURE: VBI ), is pleased to announce a research collaboration with Northwestern University Feinberg School of Medicine located in Chicago, Illinois.The collaboration will focus on the rapid detection of low levels of bacteria in clinical blood samples, as well the quantitative assessment of immune biomarkers related to sepsis.

Read More

Vivione Biosciences Inc. Announces 30 Day Warrant Reduction

DALLAS, TX-- (Marketwired - May 04, 2015 ) -Vivione Biosciences Inc. ("Vivione" or the "Company" ) (TSX VENTURE: VBI ) Further to the Company's press release dated April 22, 2015, the Company has received TSX Venture Exchange approval for the 30 day price amendment...

Read More

Vivione Biosciences Announces Successful Completion of Its Early - Stage Pilot Study at the Cleveland Clinic

 

DALLAS, TX-- (Marketwired - December 16, 2014 ) - Vivione Biosciences Inc. ("Vivione ") (TSX VENTURE: VBI) is pleased to announce the successful completion of its early stage pilot study at the Cleveland Clinic focused on applying its RAPID-B bacterial detection platform to the primary screening of suspected urinary tract infections (UTIs).

Read More

Vivione Biosciences Inc. Announces Stock Option Grant and Clarification on Warrant Extension

 

DALLAS, Texas – Vivione Biosciences Inc. (“Vivione ” or the “ Company ”) ( TSXV : VBI ), announces that options to purchase 880,000 common shares of the Company were granted today to an officer of the Company with an exercise price of $0.25 per share, expiring ten years from the date of grant and with one-third of such options vesting immediately and on each of the first and second year anniversary from the date of grant.

Read More

Vivione Biosciences Inc. Announces Warrant Extension

 

DALLAS, Texas – Vivione Biosciences Inc. (“Vivione ” or the “ Company ”) ( TSXV : VBI ), is pleased to announce that the TSX Venture Exchange (the “Exchange”) has approved the extension of the expiry date of 12,000,000 common share purchase warrants (the “Warrants”) issued to subscribers as part of the Company’s prospectus financing which closed on April 19, 2013.

Read More

Vivione Biosciences Inc. announces agreement with Litmus, LLC for Molecular Design Rights

 

LITTLE ROCK, Arkansas . - Vivione Biosciences Inc. (“Vivione ”) ( TSXV : VBI ) through its wholly owned subsidiary, Vivione Biosciences, LLC, announced today that through a new agreement(the “ Amending Agreement ”) with Litmus, LLC(“ Litmus ”), Vivione has acquired Litmus ’ 50 % royalty interest in net proceeds derived from the Molecular Design technology.

Read More

Vivione Biosciences Inc.chief executive officer interviewed by CEOCFO Magazine.

 

Calgary, Alberta : March 25, 2014 – Kevin Kuykendall, Chief Executive Officer of Vivione Biosciences Inc. ( “ Vivione ” or the “Company ”) (TSXV : VBI ) was recently interviewed by Lynn Fosse, Senior Editor of CEOCFO Magazine in response to the Company ’ s developmental successes in the commercialization of the RAPID B platform over the past year.For the full article and additional details, please visit www.vivonebiosciences.com .

Read More

Vivione Biosciences Inc. announces closing of the private placement offering with the arkansas venture capital investment trust

 

Calgary, Alberta : February 20, 2014 - Vivione Biosciences Inc. (“Vivione ” or the “ Company ”) (TSXV : VBI ) is pleased to announce that it has successfully completed its previously announced non - brokered private placement offering of 864, 000 units at a purchase price of $0 .25 per unit for total proceeds of $216, 000(the “ Offering ”). Each unit consists of one class “ A ” common share in the capital of the Corporation( “ Class A Common Shares ”) and one half of one non - transferable Class A Common Share purchase warrant(each whole warrant, a “ Warrant ”). Each Warrant entitles the holder to purchase one Class A Common Share at an exercise price of $0 .35 at any time prior to 4 : 30 p.m. (Calgary time ) on February 19, 2016, subject to accelerated expiry in certain circumstances.

Read More

Disclosure

Please read the terms and conditions section of this website carefully before using the Vivione Biosciences Inc. (the “Company”) web site. By accessing or using this site, you agree to the terms and conditions as set out in the terms and conditions section of this web site. You should review the terms and conditions section regularly as it may change at any time at our sole discretion. If you do not agree to any term or condition, you should not access or otherwise use this site.

General information regarding the Company set forth on the following pages of this website, including management 's assessment of the Company' s future plans and operations contains forward looking statements that involve substantial known and unknown risks and uncertainties.Wherever possible, words such as "may", '' would ", " could ", " should ", " will ", " anticipate ", " believe ", " plan ", " expect ", " intend ", " estimate ", " aim ", " endeavour " and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs based on its experience and expertise with respect to future events and are based on information currently available to management. Management uses forward-looking statements because it believes they provide useful information with respect to the Company, and cautions readers that the information may not be appropriate for other purposes and should not be read as guarantees of future performance or results.

Forward looking statements are subject to numerous risks and uncertainties, some of which are beyond the management and the Company ’ s control, including but not limited to, the impact of general economic conditions, industry conditions, fluctuation of foreign exchange rates, imperfection of estimates, industry competition, availability of qualified personnel and management, stock market volatility, timely and cost effective access to sufficient capital from internal and external sources, ability to integrate and realize anticipated benefits from acquisitions, ability to resell third party network communications at favorable rates, and to effectively manage growth.The Company 's actual results, performance or achievement could differ materially from those expressed in or implied by, these forward looking statements and accordingly, no assurance can be given that any of the events anticipated to occur or transpire from the forward looking statements will provide any benefits to the Company. All data presented herein should be read in conjunction with the Company' s regulatory filings with the appropriate securities regulatory authorities and the System for Electronic Document Analysis and Retrieval( “ SEDAR ”). Copies of these filings are available for review under the Company 's SEDAR profile at www.sedar.com.

Number of U.S.Foodborne Illness Cases Stalled: CDC

Little Rock firm develops rapid test for E.coli < /em> bacteria

Vivione Biosciences Donates Lab Equipment to UAPB Fisheries

E.Coli < /em> Fears Prompt Massive Frozen Food Recall

UA announces collaboration to protect consumers from food contamination